Navigation Links
SV Life Sciences Promotes 30-Year MedTech Veteran Paul LaViolette to Partner
Date:1/6/2011

BOSTON, SAN FRANCISCO and LONDON, Jan. 6, 2011 /PRNewswire/ -- SV Life Sciences ("SVLS") today announced the promotion of Paul LaViolette to Partner. Mr. LaViolette joined SVLS in early 2009 as Venture Partner.

"Since joining SVLS, Paul has successfully applied his tremendous experience with large-scale medical technology businesses to our portfolio of development stage companies," said David Milne, SVLS Managing Partner. "In doing so, Paul has underscored a key component to the SVLS value proposition. Consistently, we have attracted highly talented healthcare operators and executives from the life sciences fields and made them long-term members of our investment team. I know I speak on behalf of the entire firm in congratulating Paul on his promotion."

At SVLS, Mr. LaViolette has attracted novel deal flow that has led to multiple new investments and investment options. He has assumed board and advisory roles for a number of existing SVLS portfolio companies including TransEnterix, CardioFocus, ValenTx, MindFrame and Altura Medical. In addition to these positions, he serves on the boards of Cameron Health, Conceptus, DC Devices, Direct Flow Medical, DJO Global, Thoratec, Trans 1, and the Medical Device Manufacturers Association (MDMA), giving him broad and ongoing exposure to the medical device and technology industries.

Mr. LaViolette has 30 years of global medical technology marketing and general management experience. Most recently, he was with Boston Scientific Corporation, where he served as COO, Group President, President-Cardiology and President-International. During his tenure, the Company grew revenues over 20 times. He also spearheaded over 20 acquisitions and led extensive product development, operations and worldwide commercial organizations.  Prior to that, he held marketing and general management positions at CR Bard and various marketing roles at Kendall (Covidien). Mr. LaViolette has also served on the boards of Urologix, Percutaneous Valve Technologies and Advamed.  He received his BA in Psychology from Fairfield University and his MBA from Boston College.

Mr. LaViolette is a member of SVLS' team of 32 professionals organized according to experience and specialization into three practice areas: Biotechnology / Biopharmaceuticals; Medical Devices / Instrumentation; and Healthcare Services. These individuals' diverse and complimentary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives, called Venture Partners, who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. When possible, these individuals are promoted to serve as Partners and ultimately as Managing Partners within the Firm. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds.

About SV Life SciencesSV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The Firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company's website at http://www.svlsa.com.Contact: Denise Marks
Partner
SV Life Sciences
T: +1 617 367 8100

Email: Denise.Marks@SVLSA.com

Roland Tomforde

Managing Director
Broadgate Consultants
T : +1 212 232 2222
Email: rtomforde@broadgate.com
'/>"/>

SOURCE SV Life Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
2. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
3. InfraReDx Awarded 2010 Tax Incentive From Massachusetts Life Sciences Center
4. Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens
5. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
6. Ambit Biosciences Initiates Two Phase I Clinical Trials
7. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
8. Cell Biosciences Announces US Patent Issuance
9. Caliper Life Sciences to Acquire Cambridge Research & Instrumentation
10. Reportlinker Adds Gilead Sciences: PharmaVitae Profile
11. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):